The fourth level (definite bvAD) is assigned through histopathological or genetic confirmation of AD (ie, by the presence of pathogenic APP, PSEN1, or PSEN2 genetic variations) in conjunction with a bvAD clinical syndrome. The gene discussed is PSEN2; the disease is Alzheimer disease.